{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:02:42Z","timestamp":1792598562442,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier","isbn-type":[{"value":"9780128177389","type":"print"}],"license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"DOI":"10.1016\/bs.pmbts.2018.12.006","type":"book-chapter","created":{"date-parts":[[2019,3,9]],"date-time":"2019-03-09T12:42:31Z","timestamp":1552135351000},"page":"187-198","source":"Crossref","is-referenced-by-count":24,"title":["Serum CA50 levels in patients with cancers and other diseases"],"prefix":"10.1016","author":[{"given":"Ming","family":"Shan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingwu","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/bs.pmbts.2018.12.006_bb0010","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1159\/000233384","article-title":"Monoclonal antibodies against gastrointestinal tumour-associated antigens isolated as monosialogangliosides","volume":"71","author":"Lindholm","year":"1983","journal-title":"Int Arch Allergy Appl Immunol"},{"key":"10.1016\/bs.pmbts.2018.12.006_bb0015","series-title":"Clinical Glycobiology","author":"Zhang","year":"2017"},{"issue":"3","key":"10.1016\/bs.pmbts.2018.12.006_bb0020","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3109\/00365529208999944","article-title":"Tumour markers CA 19-9 and CA 50 in digestive tract malignancies","volume":"27","author":"Haglund","year":"1992","journal-title":"Scand J Gastroenterol"},{"issue":"1","key":"10.1016\/bs.pmbts.2018.12.006_bb0025","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/0005-2760(85)90182-1","article-title":"Chemical structure of carcinoma ganglioside antigens defined by monoclonal antibody C-50 and some allied gangliosides of human pancreatic adenocarcinoma","volume":"834","author":"Mansson","year":"1985","journal-title":"Biochim Biophys Acta"},{"issue":"7","key":"10.1016\/bs.pmbts.2018.12.006_bb0030","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/0959-8049(94)90154-6","article-title":"CA50 as a serum marker for pancreatic carcinoma: comparison with CA19-9","volume":"30A","author":"Pasquali","year":"1994","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/bs.pmbts.2018.12.006_bb0035","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/0014-5793(85)80341-0","article-title":"Sialosyllactotetraosylceramide, a novel ganglioside antigen detected in human carcinomas by a monoclonal antibody","volume":"182","author":"Nilsson","year":"1985","journal-title":"FEBS Lett"},{"issue":"34","key":"10.1016\/bs.pmbts.2018.12.006_bb0040","doi-asserted-by":"crossref","first-page":"16370","DOI":"10.1016\/S0021-9258(18)49265-4","article-title":"Developmental changes of gangliosides of the rat stomach. Appearance of a blood group B-active ganglioside","volume":"262","author":"Bouhours","year":"1987","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/bs.pmbts.2018.12.006_bb0045","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/00006676-199303000-00004","article-title":"Serum levels of CA 19-9 and CA 50 in relation to Lewis blood cell status in patients with malignant and benign pancreatic disease","volume":"8","author":"von Rosen","year":"1993","journal-title":"Pancreas"},{"issue":"3","key":"10.1016\/bs.pmbts.2018.12.006_bb0050","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/172460088900400306","article-title":"Efficiency of composite laboratory tests in the diagnosis of liver malignancies","volume":"4","author":"Pavesi","year":"1989","journal-title":"Int J Biol Markers"},{"issue":"4","key":"10.1016\/bs.pmbts.2018.12.006_bb0055","first-page":"283","article-title":"A comparison of pretreatment serum levels of four tumor markers in patients with endometrial and cervical carcinoma","volume":"11","author":"Gadducci","year":"1990","journal-title":"Eur J Gynaecol Oncol"},{"issue":"3","key":"10.1016\/bs.pmbts.2018.12.006_bb0060","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/BF01648448","article-title":"The detection of colorectal carcinomas with the use of CA-50 radioimmunoassay inhibition test","volume":"1","author":"Habib","year":"1986","journal-title":"Int J Colorectal Dis"},{"issue":"2","key":"10.1016\/bs.pmbts.2018.12.006_bb0065","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/bjc.1992.44","article-title":"Sensitivity and specificity of CA242 in gastro-intestinal cancer. A comparison with CEA, CA50 and CA 19-9","volume":"65","author":"Nilsson","year":"1992","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/bs.pmbts.2018.12.006_bb0070","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s11033-011-0751-0","article-title":"Are biomarkers correlated with recurrence patterns in patients with resectable gastric adenocarcinoma","volume":"39","author":"Li","year":"2012","journal-title":"Mol Biol Rep"},{"issue":"2","key":"10.1016\/bs.pmbts.2018.12.006_bb0075","doi-asserted-by":"crossref","first-page":"170","DOI":"10.5306\/wjco.v5.i2.170","article-title":"Prognostic value of preoperative serum tumor markers in gastric cancer","volume":"5","author":"Huang","year":"2014","journal-title":"World J Clin Oncol"},{"issue":"3","key":"10.1016\/bs.pmbts.2018.12.006_bb0080","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/BF00295845","article-title":"CA-50 serum level in patients with prostate cancer","volume":"18","author":"Marczynska","year":"1990","journal-title":"Urol Res"},{"issue":"5","key":"10.1016\/bs.pmbts.2018.12.006_bb0085","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1507\/endocrj1954.38.565","article-title":"Serum levels and thyroid tissue expression of CA50 and CA 19-9 in patients with thyroid tumor","volume":"38","author":"Matsuura","year":"1991","journal-title":"Endocrinol Jpn"},{"issue":"5","key":"10.1016\/bs.pmbts.2018.12.006_bb0090","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/bjc.1991.422","article-title":"Elevated serum levels of Dupan-2 in pancreatic cancer patients negative for Lewis blood group phenotype","volume":"64","author":"Kawa","year":"1991","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/bs.pmbts.2018.12.006_bb0095","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/ijc.2910380610","article-title":"Tissue expression of the tumor marker CA 50 in benign and malignant pancreatic lesions. A comparison with CA 19-9","volume":"38","author":"Haglund","year":"1986","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/bs.pmbts.2018.12.006_bb0100","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/BF02925701","article-title":"Tissue expression of the cancer-associated antigens CA 19-9 and CA-50 in chronic pancreatitis and pancreatic carcinoma","volume":"5","author":"Schwenk","year":"1989","journal-title":"Int J Pancreatol"},{"issue":"6","key":"10.1016\/bs.pmbts.2018.12.006_bb0105","first-page":"641","article-title":"Combined detection of serum tumor markers for differential diagnosis of solid lesions located at the pancreatic head","volume":"6","author":"Liao","year":"2007","journal-title":"Hepatobiliary Pancreat Dis Int"},{"issue":"6","key":"10.1016\/bs.pmbts.2018.12.006_bb0110","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1159\/000281740","article-title":"Prognostication of bladder carcinoma by immunohistochemistry: refined and combined analysis of staining for MCA and CA50","volume":"45","author":"Lipponen","year":"1990","journal-title":"Urol Int"},{"issue":"1","key":"10.1016\/bs.pmbts.2018.12.006_bb0115","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0304-3835(99)00161-5","article-title":"Mucin expression in mucinous carcinoma and other invasive carcinomas of the breast","volume":"142","author":"Chu","year":"1999","journal-title":"Cancer Lett"},{"issue":"3A","key":"10.1016\/bs.pmbts.2018.12.006_bb0120","first-page":"1755","article-title":"Immunohistochemical studies of mucinous mammary carcinomas and their metastases","volume":"25","author":"Gunkel","year":"2005","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/bs.pmbts.2018.12.006_bb0125","first-page":"91","article-title":"Expression of tumour markers CA50, CEA and TPA in female breast carcinoma as related to histopathological findings and survival","volume":"12","author":"Eskelinen","year":"1992","journal-title":"Anticancer Res"},{"issue":"5\u20136","key":"10.1016\/bs.pmbts.2018.12.006_bb0130","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1159\/000217780","article-title":"Coexpression of ganglioside antigen Fuc-GM1, neural-cell adhesion molecule, carcinoembryonic antigen, and carbohydrate tumor-associated antigen CA 50 in lung cancer","volume":"13","author":"Brezicka","year":"1992","journal-title":"Tumour Biol"},{"issue":"2","key":"10.1016\/bs.pmbts.2018.12.006_bb0135","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/00008469-199504000-00002","article-title":"Clinical tumour markers in lung cancer","volume":"4","author":"Niklinski","year":"1995","journal-title":"Eur J Caner Prev"},{"issue":"1","key":"10.1016\/bs.pmbts.2018.12.006_bb0140","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0954-6111(94)90170-8","article-title":"Serum and pleural fluid levels of CA50 in malignant and tuberculous effusions","volume":"88","author":"Yang","year":"1994","journal-title":"Respir Med"},{"issue":"6","key":"10.1016\/bs.pmbts.2018.12.006_bb0145","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/j.1445-2197.2012.06287.x","article-title":"Prognostic significance of tumour markers in Chinese patients with gastric cancer","volume":"84","author":"Liu","year":"2014","journal-title":"ANZ J Surg"},{"key":"10.1016\/bs.pmbts.2018.12.006_bb0150","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/1477-7819-10-68","article-title":"Prognostic significance of tumor markers in T4a gastric cancer","volume":"10","author":"Liu","year":"2012","journal-title":"World J Surg Oncol"},{"issue":"5","key":"10.1016\/bs.pmbts.2018.12.006_bb0155","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1177\/030089168907500519","article-title":"Tumor markers in serum of patients with primary squamous cell carcinoma of the esophagus","volume":"75","author":"Gion","year":"1989","journal-title":"Tumori"},{"issue":"2","key":"10.1016\/bs.pmbts.2018.12.006_bb0160","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/(SICI)1097-0215(19970422)74:2<233::AID-IJC17>3.0.CO;2-E","article-title":"Evaluation of five glycoprotein tumour markers (CEA, CA-50, CA-19-9, CA-125, CA-15-3) for the prognosis of renal-cell carcinoma","volume":"74","author":"Grankvist","year":"1997","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/bs.pmbts.2018.12.006_bb0165","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/ijc.2910470103","article-title":"CA 50 determination in body fluids: can we screen patients at risk for gastric cancer?","volume":"47","author":"Farinati","year":"1991","journal-title":"Int J Cancer"},{"issue":"9","key":"10.1016\/bs.pmbts.2018.12.006_bb0170","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1002\/1097-0142(19940501)73:9<2305::AID-CNCR2820730911>3.0.CO;2-D","article-title":"Quantitative analysis of carcinoembryonic antigen, squamous cell carcinoma antigen, CA 125, and CA 50 cytosolic content in non-small cell lung cancer","volume":"73","author":"Picardo","year":"1994","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/bs.pmbts.2018.12.006_bb0175","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1002\/1097-0142(19920415)69:8<2036::AID-CNCR2820690805>3.0.CO;2-M","article-title":"Evaluation of seven tumor markers (CA 50, CA 19-9, CA 19-9 TruQuant, CA 72-4, CA 195, carcinoembryonic antigen, and tissue polypeptide antigen) in the pretreatment sera of patients with gastric carcinoma","volume":"69","author":"Wobbes","year":"1992","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/bs.pmbts.2018.12.006_bb0180","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.aca.2007.07.052","article-title":"Evaluation of carbohydrate antigen 50 in human serum using magnetic particle-based chemiluminescence enzyme immunoassay","volume":"598","author":"Wang","year":"2007","journal-title":"Anal Chim Acta"},{"issue":"1\u20132","key":"10.1016\/bs.pmbts.2018.12.006_bb0185","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0003-2670(03)00809-2","article-title":"Clinical applications of chemiluminescence","volume":"500","author":"Kricka","year":"2003","journal-title":"Anal Chim Acta"},{"issue":"2","key":"10.1016\/bs.pmbts.2018.12.006_bb0190","first-page":"383","article-title":"Application values of detection of serum CA199, CA242 and CA50 in the diagnosis of pancreatic cancer","volume":"31","author":"Lei","year":"2017","journal-title":"J Biol Regul Homeost Agents"},{"issue":"5","key":"10.1016\/bs.pmbts.2018.12.006_bb0195","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/ijc.2910480521","article-title":"Comparison of serological expression of different epitopes on the CA50-carrying antigen CanAg","volume":"48","author":"Johansson","year":"1991","journal-title":"Int J Cancer"},{"issue":"4","key":"10.1016\/bs.pmbts.2018.12.006_bb0200","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1097\/SLA.0000000000001741","article-title":"Potential biomarkers in Lewis negative patients with pancreatic cancer","volume":"265","author":"Luo","year":"2017","journal-title":"Ann Surg"},{"key":"10.1016\/bs.pmbts.2018.12.006_bb0205","doi-asserted-by":"crossref","first-page":"46345","DOI":"10.1038\/srep46345","article-title":"Nomograms for predicting the prognostic value of serological tumor biomarkers in colorectal cancer patients after radical resection","volume":"7","author":"Li","year":"2017","journal-title":"Sci Rep"},{"issue":"2\u20134","key":"10.1016\/bs.pmbts.2018.12.006_bb0210","first-page":"283","article-title":"A comparison of the clinical usefulness of CA 19-9 and CA 50 in the diagnosis and monitoring of gastrointestinal cancers","volume":"15","author":"Kokocinska","year":"1996","journal-title":"J Environ Pathol Toxicol Oncol"}],"container-title":["Progress in Molecular Biology and Translational Science","Glycans and Glycosaminoglycans as Clinical Biomarkers and Therapeutics - Part A"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877117318301546?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877117318301546?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T16:04:30Z","timestamp":1663085070000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1877117318301546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"ISBN":["9780128177389"],"references-count":41,"URL":"https:\/\/doi.org\/10.1016\/bs.pmbts.2018.12.006","relation":{},"ISSN":["1877-1173"],"issn-type":[{"value":"1877-1173","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]}}}